Cervomed INC

CervoMed Inc. announced its drug candidate neflamapimod has received an Innovation Passport under the UK's Innovative Licensing and Access Pathway (ILAP) for the treatment of Dementia with Lewy Bodies (DLB).

CervoMed Inc. announced new clinical, plasma biomarker, and imaging data for its drug candidate neflamapimod at the Alzheimer's Association International Conference 2026, reinforcing its potential in treating Dementia with Lewy Bodies (DLB).

CervoMed Inc. announced the completion of patient enrollment for its Phase 2a study of neflamapimod, an investigational drug for nonfluent variant primary progressive aphasia (nfvPPA), a form of frontotemporal dementia.

CervoMed Inc. announced it has received a notice of allowance from the USPTO for a new patent covering its drug candidate, neflamapimod, for treating dementia with Lewy bodies.

CervoMed Inc. has released an 8-K filing detailing business updates, clinical study information, development plans, and financial position, made available on their website.

CervoMed Inc. announced a $10.5 million private placement financing to advance its drug candidate neflamapimod and focus on strategic partnerships.

CervoMed Inc. reported a wider net loss for Q1 2026 due to decreased grant revenue and increased operating expenses, while cash reserves remain a concern for continued operations.

CervoMed Inc. reported increased net losses and significant cash burn in Q3 2025, alongside positive Phase 2b neflamapimod data for DLB and FDA alignment for a pivotal Phase 3 trial, while facing substantial doubt about its ability to continue as a going concern.

CervoMed Inc. reports increased net losses and cash burn in Q2 2025, while its lead drug candidate neflamapimod shows promising clinical results in ongoing trials for neurodegenerative disorders.

CervoMed Inc. announces its Q1 2025 financial results, highlighting a net loss of $4.9 million and provides updates on its ongoing clinical trials, including positive 16-week extension data from the RewinD-LB Trial.

CervoMed Inc. announced its Q3 2024 financial results, highlighting progress in its clinical trials and financial position.

CervoMed Inc. announced its Q2 2024 financial results and the completion of enrollment in its Phase 2b RewinD-LB trial for Early-Stage DLB.

CervoMed Inc. reported a significant net loss of $27.0 million for 2025, while advancing its lead drug candidate, neflamapimod, to a planned Phase 3 trial for Dementia with Lewy Bodies, despite ongoing funding needs.

CervoMed Inc. announces positive 16-week extension data from its RewinD-LB Trial, signaling potential advancement of neflamapimod as a treatment for Dementia with Lewy Bodies (DLB) and setting the stage for a Phase 3 trial.

CervoMed Inc.'s 10-K filing details the company's focus on developing neflamapimod for age-related neurological disorders, particularly Dementia with Lewy Bodies (DLB), and its ongoing Phase 2b clinical trial.

Director Joshua S. Boger acquired 955,414 units of CervoMed Inc. through a private placement, signaling significant insider confidence.

Director Frank Zavrl was granted an option to purchase 8,150 shares of CervoMed common stock following his election to the board.

Director Marwan Sabbagh was granted options to purchase 8,150 shares of CervoMed common stock following his election to the board.

Director David Quigley was granted options to purchase 8,150 shares of CervoMed Inc. common stock following his election to the board.

Director Jeffrey V. Poulton was granted 8,150 stock options as part of CervoMed Inc.'s non-employee director compensation policy.

Director Jane Hollingsworth was granted an option to purchase 8,150 shares of CervoMed common stock following her election to the board.

CervoMed Inc. is asking stockholders to approve the CervoMed Inc. 2025 Equity Incentive Plan at the upcoming annual meeting.

CervoMed Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 14, 2024, to elect directors, ratify the selection of an independent accounting firm, and conduct an advisory vote on executive compensation.

CervoMed files an amendment to its S-1 registration statement to allow selling stockholders to resell up to 5,064,570 shares of common stock issued in a private placement.

CervoMed is registering the resale of approximately 5.1 million shares of its common stock following a recent private placement.

Dr. Joshua S. Boger reports a 20% beneficial ownership stake in CervoMed Inc. following a recent private placement.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G, indicating a reduction in their beneficial ownership of CervoMed Inc. common stock to below the 5% threshold.

CVI Investments, Inc. and Heights Capital Management, Inc. have filed a Schedule 13G reporting a 5.5% beneficial ownership stake in CervoMed Inc.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed a Schedule 13G, reporting beneficial ownership of 8.0% of CervoMed Inc. common stock as of March 31, 2026.

AWM Investment Company, Inc. reports beneficial ownership of 405,165 warrants in CervoMed Inc., representing 4.2% of the class, as of March 31, 2026.

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported a combined beneficial ownership of 5.1% in CervoMed Inc's common stock.

RA Capital Management amends its Schedule 13G filing for CervoMed Inc. to correct a clerical error regarding beneficial ownership of shares underlying warrants.